Also known as Aspirin, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial infarction (MI) .
Interestingly, the results of various studies have demonstrated that long-term use of acetylsalicylic acid may decrease the risk of various cancers, including colorectal, esophageal, breast, lung, prostate, liver and skin cancer . Aspirin is classified as a non-selective cyclooxygenase (COX) inhibitor and is available in many doses and forms, including chewable tablets, suppositories, extended release formulations, and others .
Acetylsalicylic acid is a very common cause of accidental poisoning in young children. It should be kept out of reach from young children, toddlers, and infants .
Pain, fever, and inflammation
Acetylsalicylic acid (ASA), in the regular tablet form (immediate-release), is indicated to relieve pain, fever, and inflammation associated with many conditions, including the flu, the common cold, neck and back pain, dysmenorrhea, headache, tooth pain, sprains, fractures, myositis, neuralgia, synovitis, arthritis, bursitis, burns, and various injuries. It is also used for symptomatic pain relief after surgical and dental procedures .
The extra strength formulation of acetylsalicylic acid is also indicated for the management migraine pain with photophobia (sensitivity to light) and phonophobia (sensitivity to sound).
Other indications
ASA is also indicated for various other purposes, due to its ability to inhibit platelet aggregation. These include:
Reducing the risk of cardiovascular death in suspected cases of myocardial infarction (MI) .
Reducing the risk of a first non-fatal myocardial infarction in patients, and for reducing the risk of morbidity and mortality in cases of unstable angina and in those who have had a prior myocardial infarction .
For reducing the risk of transient ischemic attacks (TIA) and to prevent atherothrombotic cerebral infarction (in conjunction with other treatments) .
For the prevention of thromboembolism after hip replacement surgery .
For decreasing platelet to platelet adhesion following carotid endarterectomy, aiding in the prevention of transient ischemic attacks (TIA) .
Used for patients undergoing hemodialysis with a silicone rubber arteriovenous cannula inserted to prevent thrombosis at the insertion site .
Important note regarding use of the extended-release formulation
In the setting of acute myocardial infarction, or before percutaneous interventions, the extended-release form of acetylsalicylic acid should not be used. Use immediate-release formulations in scenarios requiring rapid onset of action . The extended-release form is taken to decrease the incidence of mortality and myocardial infarction (MI) for individuals diagnosed with chronic coronary artery disease (CAD), including patients with previous myocardial infarction (MI) or unstable angina or with chronic stable angina. Additionally, the extended-release form is used to decrease the risk of death and recurrent episodes of stroke in patients with a history of stroke or TIA .
Division of Cardiology, Department of Internal Medicine, severance hospital, Seoul, Korea, Republic of
Prince Sultan Cardiac Center, Riyadh, Saudi Arabia
Community Heart and Vascular Hospital, Indianapolis, Indiana, United States
North Memorial Medical Center, Minneapolis, Minnesota, United States
IU Health North Medical Center, Carmel, Indiana, United States
Research Site, St Paul, Minnesota, United States
St-Paul's Hospital, Vancouver, British Columbia, Canada
IUCPQ, Quebec, Canada
Washington University, Saint Louis, Missouri, United States
The Alfred Hospital, Melbourne, Victoria, Australia
Yaguo Li, Hangzhou, Zhejiang, China
Saiseikai Yokohama-City Eastern Hospital, Yokohama City, Kanagawa-ken, Japan
Tokyo Women's Medical University Hospital, Shinjuku-ku, Tokyo-to, Japan
Sakakibara Heart Institute, Japan Research Promotion Society for Cardiovascular Diseases, Fuchu-shi, Tokyo, Japan
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
University of Michigan, Ann Arbor, Michigan, United States
Bridgeport Hospital, Bridgeport, Connecticut, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.